Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
Article 2014 en
Authors
KO
Kiwamu Okita
NI
Namiki Izumi
OM
Osamu Matsui
Abstract
1 min read
Although the superiority of peretinoin to placebo could not be validated, 600 mg/day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-HCC, particularly after 2 years. The efficacy and safety of peretinoin 600 mg/day should continue to be evaluated in further studies.
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar‐Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie Tung‐Ping Poon, Kwang–Hyub Han, Won Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabrício Henrique Pereira De Souza, Marie‐Aude Le Berre, Gerold Meinhardt, Josep M. Llovet
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie T.P. Poon, Kwang–Hyub Han, Won Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabrício Henrique Pereira De Souza, Marie-Aude Le Berre, Gerold Meinhardt, Josep M. Llovet
Discussion(0)
No comments yet. Be the first to comment.